Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension
- 1 March 2018
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 314 (3) , L349-L359
Abstract
Prostacyclin agonists that bind the prostacyclin receptor (IP) to stimulate cAMP synthesis are effective vasodilators for the treatment of idiopathic pulmonary arterial hypertension (IPAH), but this signaling may occur through nuclear peroxisome proliferator-activated receptor-γ (PPARγ). There is evidence of scant IP and PPARγ expression but stable prostanoid EP4 receptor (EP4) expression in IPAH patients. Both IP and EP4 functionally couple with stimulatory G protein (Gs), which activates signal transduction. We investigated the effect of an EP4-specific agonist on pulmonary arterial remodeling and its regulatory mechanisms in pulmonary arterial smooth muscle cells (PASMCs). Immunoblotting evealed IP, EP4, and PPARγ expression in human pulmonary arterial hypertension (PAH) and monocrotaline (MCT)-induced PAH rat lung tissue. Isolated PASMCs from MCT-induced PAH rats (MCT-PASMCs) were treated with L-902,688, a selective EP4 agonist, to investigate the anti-vascular remodeling effect. Scant expression of IP and PPARγ but stable expression of EP4 was observed in IPAH patient lung tissues and MCT-PASMCs. L-902,688 inhibited IP-insufficient MCT-PASMC proliferation and migration by activating PPARγ in a time- and dose-dependent manner, but these effects were reversed by AH-23848 (an EP4 antagonist) and H-89 [a protein kinase A (PKA) inhibitor], highlighting the crucial role of PPARγ in the activity of this EP4 agonist. L-902,688 attenuated pulmonary arterial remodeling in hypoxic PAH mice and MCT-induced PAH rats; therefore, we conclude that the selective EP4 agonist L-902,688 reverses vascular remodeling by activating PPARγ. This study identified a novel EP4-PKA-PPARγ pathway, and we propose EP4 as a potential therapeutic target for PAH.Keywords
Funding Information
- National Science Council Taiwan (NSC) (NSC 101-2314-B-182-076-MY3)
- Chang Gung Medical Foundation (CMRPD1B001-3, CMRPD1E0331-3, CMRPD1C0331-2, BMRPD05)
- Ministry of Science and Technology (MOST 103-2314-B-182-060-MY2)
- Taiwan Health Foundation
- Gary and Amy foundation
This publication has 46 references indexed in Scilit:
- E-type prostanoid receptor 4 (EP4) in disease and therapyPharmacology & Therapeutics, 2013
- Ca2+ signals evoked by histamine H1 receptors are attenuated by activation of prostaglandin EP2 and EP4 receptors in human aortic smooth muscle cellsBritish Journal of Pharmacology, 2013
- Molecular pathogenesis of pulmonary arterial hypertensionJournal of Clinical Investigation, 2012
- EP4 receptor as a new target for bronchodilator therapyThorax, 2011
- Smooth Muscle Proliferation and Role of the Prostacyclin (IP) Receptor in Idiopathic Pulmonary Arterial HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injuryCardiovascular Research, 2008
- Vasorelaxation induced by prostaglandin E2in human pulmonary vein: role of the EP4receptor subtypeBritish Journal of Pharmacology, 2008
- Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator‐Activated Receptor‐γ: Therapeutic Implications for Cardiovascular DiseasesPPAR Research, 2007
- Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung DiseasePPAR Research, 2007